ClinicalTrials.gg
CompletedNCT07129174Updated Nov 9, 2026

Pulmonary Microbiota Changes and Clinical Outcomes in Neurosurgical ICU Patients With Artificial Airways

An observational study in Ventilator-Associated Pneumonia (VAP), Intensive Care Unit (ICU) Patients and Microbiome Dysbiosis, sponsored by Jian-Xin Zhou. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Jian-Xin Zhou · Observational

How we know

Updated Nov 9, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
246
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.

Started
2025
with 4 others
Observational
9 of 26
4 open now
Registered
21st of 26
by date

Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is one of 5 that started in 2025, is one of 9 observational ones, and was the 21st registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pneumonia, Ventilator-Associated with a site in China, or all of them as a file.
02

Study summary

After neurosurgery, many patients need to stay in the intensive care unit (ICU) and use a breathing machine (mechanical ventilation) because of issues like decreased consciousness, weak breathing, or poor airway protection. During this period, the natural balance of bacteria in the lungs-known as the lung microbiota-can be disturbed by surgery, antibiotics, and airway procedures. This may reduce healthy bacteria and allow harmful bacteria to grow, increasing the risk of lung infections such as ventilator-associated pneumonia (VAP).

This study will follow 220 postoperative neurosurgical ICU patients at three centers: Beijing Tiantan Hospital, Beijing Shijitan Hospital, and Beijing Anzhen Hospital from August 2025 to August 2026. These patients will include those undergoing surgery for brain tumors, brain hemorrhage, or traumatic brain injury. Airway secretion samples (tracheal aspirates) will be collected shortly after surgery and at several subsequent time points to assess how lung bacteria change over time while patients are using a breathing machine.

Using advanced laboratory methods, the investigators will measure both the amount and types of bacteria in the lungs. The aim is to determine how these changes are related to patient outcomes, such as the occurrence of lung infections.

The results of this study may contribute to earlier detection of lung infections and the development of personalized treatment plans to improve recovery in ICU patients after neurosurgery.

Read the detailed description

Postoperative neurosurgical patients represent a unique and high-risk population in the ICU, often requiring prolonged invasive mechanical ventilation due to impaired consciousness and respiratory function. During this critical period, multiple factors-including surgical trauma, antibiotic administration, and airway manipulation-can disrupt the pulmonary microbiota, potentially leading to dysbiosis characterized by reduced microbial diversity and overgrowth of opportunistic pathogens.

Emerging evidence suggests that alterations in the lung microbiota may play a key role in the development of respiratory infections, such as ventilator-associated pneumonia (VAP), and could influence the overall clinical trajectory of ICU patients. However, current knowledge regarding the temporal dynamics of the lung microbiome in neurosurgical patients is limited, and its potential as a predictive biomarker for infection risk or recovery remains unexplored.

This prospective observational cohort study is designed to systematically characterize the succession patterns of the pulmonary microbiota in adult neurosurgical patients requiring mechanical ventilation. By integrating microbial profiling with clinical data, the study aims to elucidate the relationship between microbiota changes and patient outcomes, including infection incidence, length of ICU stay, and duration of ventilation.

High-resolution microbial analysis using 16S rRNA gene sequencing and quantitative techniques (e.g., droplet digital PCR) will allow for precise tracking of microbial shifts over time. These findings may provide new perspectives on host-microbiota interactions under ICU conditions and support the development of early warning indicators for infection, as well as inform personalized antimicrobial and ventilation strategies in postoperative care.

Ultimately, the study seeks to improve understanding of lung microbiome evolution in response to surgical and critical care interventions and to identify clinically relevant microbial patterns that may serve as novel prognostic tools in neurosurgical ICU populations.

03

Conditions studied

  • Ventilator-Associated Pneumonia (VAP)
  • Intensive Care Unit (ICU) Patients
  • Microbiome Dysbiosis

Keywords

  • Ventilator-Associated Pneumonia (VAP)
  • Intensive care unit (ICU)
  • Pulmonary Microbiota
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will include 220 adult (≥18 years) postoperative neurosurgical patients admitted for the first time to the ICUs of three centers: Beijing Tiantan Hospital, Beijing Shijitan Hospital, and Beijing Anzhen Hospital between August 2025 and August 2026. Eligible patients will have undergone brain tumor surgery, subarachnoid hemorrhage surgery, or traumatic brain injury surgery and be expected to require artificial airway support for more than 24 hours. Inclusion and exclusion criteria will be applied to ensure a consistent, well-defined high-risk ICU population for evaluating clinical outcomes and associated factors.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet all of the following conditions to be eligible for inclusion:

    1. First admission to the Intensive Care Unit (ICU).
    2. Assessed by an ICU specialist as expected to require artificial airway support (e.g., mechanical ventilation) for more than 24 hours.
    3. Neurosurgical patients. Postoperative neurosurgical patients are defined in this study as those who have undergone surgery for: brain tumors, Subarachnoid hemorrhage, Traumatic brain injury

Exclusion criteria

Exclusion Criteria:

  • Patients meeting any of the following criteria will be excluded:

    1. Age under 18 years
    2. Pregnancy
    3. Pre-existing spinal cord injury
    4. History of chronic pulmonary diseases, including: Chronic bronchitis, (COPD), Bronchial asthma, Bronchiectasis, Interstitial lung disease, Pleural effusion
    5. Pre-existing conditions, including: Systemic immunomodulatory therapy, Chemotherapy, infection, Other congenital or acquired immunodeficiency disorders
    6. Receipt of systemic antimicrobial therapy within the past 3 months
    7. Diagnosis of primary lung cancer or lung from other tumors
    8. History of partial lung resection for any reason
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
246 participants (actual)
Target follow-up
28 Days
Patient registry
Yes

Groups and cohorts

  • Postoperative Neurosurgical ICU Patients

    This cohort includes adult patients admitted to the ICU for the first time following neurosurgical procedures (including brain tumor surgery, subarachnoid hemorrhage surgery, and traumatic brain injury surgery) and expected to receive invasive mechanical ventilation for more than 24 hours. Patients will undergo serial collection of tracheal aspirate samples to assess the dynamic changes in the pulmonary microbiota. No therapeutic intervention is applied; this is a prospective observational cohort study.

  • Neurosurgical Reference Cohort

    Patients scheduled to undergo neurosurgery under general anesthesia with planned endotracheal intubation. A single endotracheal aspirate sample was collected after endotracheal intubation and before surgical incision for airway microbiota profiling by 16S rRNA gene sequencing. Participants underwent subsequent clinical follow-up, with no longitudinal endotracheal aspirate sampling.

06

What researchers measure

Primary outcomes

  1. Incidence of Ventilator-Associated Pneumonia Within 28 Days of ICU Admission

    Ventilator-associated pneumonia will be diagnosed according to the 2016 IDSA/ATS guidelines. The number and proportion of participants who develop ventilator-associated pneumonia within 28 days of ICU admission will be recorded.

    Time frame: Within 28 days of ICU admission

Secondary outcomes

  1. Incidence of Early Ventilator-Associated Pneumonia Within 3 Days of ICU Admission

    Early ventilator-associated pneumonia will be defined as ventilator-associated pneumonia occurring within 3 days of ICU admission. Ventilator-associated pneumonia will be diagnosed according to the 2016 IDSA/ATS guidelines. The number and proportion of participants who develop early ventilator-associated pneumonia will be recorded.

    Time frame: Within 3 days of ICU admission

  2. ICU Length of Stay

    ICU length of stay will be defined as the number of days from ICU admission to ICU discharge. The duration of ICU stay will be recorded for each participant.

    Time frame: through study completion, an average of 7 days

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Aug 2026, 11 months.

Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 11 months is below that.

Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2025
First posted
Aug 19, 2025
StartActual
Aug 30, 2025
Primary completionActual
Aug 27, 2026was Jun 2026
CompletionActual
Aug 30, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 9, 2026
Primary completion
Jun 30, 2026→Aug 27, 2026 (actual)
Nov 9, 2026
Enrollment
220 (estimated)→246 (actual)
Nov 9, 2026
Interventions
Arms added: Neurosurgical Reference Cohort
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedIncidence of HospitalVentilator-AcquiredAssociated Pneumonia (HAP) Within 28 Days of ICU AdmissionTime frame: Within 28 days of ICU admission
Nov 9, 2026
Secondary outcomes
1 edited, 1 added, 2 removed
What changed in the outcomes
  • EditedIncidence of Early Ventilator-Associated Pneumonia (VAP) Within 283 Days of ICU AdmissionTime frame: Within 28 days of ICU admission → Within 3 days of ICU admission
  • AddedICU Length of StayTime frame: through study completion, an average of 7 days
  • RemovedAssociation Between Pulmonary Microbiota Alterations and Risk of Hospital-Acquired PneumoniaTime frame: Within 28 days of ICU admission
  • RemovedAssociation Between Pulmonary Microbiota Alterations and Risk of Ventilator-Associated PneumoniaTime frame: Within 28 days of ICU admission
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2026→Aug 27, 2026 (now actual)
    Enrollment 220 (estimated)→246 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedIncidence of HospitalVentilator-AcquiredAssociated Pneumonia (HAP) Within 28 Days of ICU AdmissionTime frame: Within 28 days of ICU admission
    Secondary outcomes 1 edited, 1 added, 2 removed
    What changed in the outcomes
    • EditedIncidence of Early Ventilator-Associated Pneumonia (VAP) Within 283 Days of ICU AdmissionTime frame: Within 28 days of ICU admission → Within 3 days of ICU admission
    • AddedICU Length of StayTime frame: through study completion, an average of 7 days
    • RemovedAssociation Between Pulmonary Microbiota Alterations and Risk of Hospital-Acquired PneumoniaTime frame: Within 28 days of ICU admission
    • RemovedAssociation Between Pulmonary Microbiota Alterations and Risk of Ventilator-Associated PneumoniaTime frame: Within 28 days of ICU admission
    Interventions Arms added: Neurosurgical Reference Cohort
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07129174
Lead sponsor
Jian-Xin Zhou
Responsible party
Jian-Xin Zhou (Professor, Capital Medical University) — Sponsor-investigator
First posted
Aug 19, 2025
Start date
Aug 30, 2025
Primary completion
Aug 27, 2026
Completion
Aug 30, 2026
Last update
Nov 9, 2026

Study contacts

Jian-Xin Zhou, MD, PhD
principal investigator · Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion